SYDNEY, AUSTRALIA: Palla Pharma Limited announced that Mr Giles Moss has been appointed as the new Chief Executive Officer (CEO) of the Company and will assume the role on September 1, 2021.
Giles brings over 30 years of commercial leadership and significant operational experience in the pharmaceutical industry to this role. Over his career, Giles has established a well-deserved reputation as both a strategic problem solver and strong business builder.
Palla Pharma Chairman Simon Moore commented “I am excited to announce Giles Moss’s appointment as CEO of Palla Pharma. Giles has a truly unique mix of skills and experience which are ideally suited to leading Palla Pharma as it seeks to realise the potential of its flexible fully integrated business model.”
In his current role of Vice President and General Manager Europe at GW Pharmaceuticals, Giles has been central to the rapid successful ex-US launch of a new highly regulated orphan medicine for epilepsy. Since 2016, Giles has built-out the core international functions and the commercial organisation across Europe.
Prior to his role at GW Pharmaceuticals, Giles held roles as General Manager, or accountable for regional P&Ls, in 24 countries across Europe and Asia Pacific. He has also held several key global and regional leadership roles including Vice President Region 1, Europe and prior to that being Head of CNS Global Marketing and Medical Affairs.
Giles’s early career allowed him a broad pharmaceutical industry experience; starting as a sales representative and moving through marketing and management roles at BMS, Sandoz and SmithKline Beecham whilst operating in multiple therapeutic areas including neurology, cardiology, oncology, infectious diseases and psychiatry.
Mr Moss said, “I am looking forward to the opportunity to lead Palla Pharma at this pivotal time. Palla is well placed to meet the need for essential opioid-based pain relief products in both the established markets of Europe and the United Kingdom and also those regions where pain relief is in short supply. And as a farm-gate to pharmacy producer, Palla’s ability to extract value at all levels of production throughout the supply chain, is unmatched in the industry.”
Giles is a UK Pharmacist, and holds a Bachelor of Science degree in Pharmacy from Manchester University and an MBA from Henley the Management College, UK. He is married with two children.
Palla Pharma Ltd
0.42 AUD +0.065 (18.06%)
26 May, 3:54 pm GMT+10 · Disclaimer
ASX: PAL
Leave a Reply